February 2010 - Volume 21 - Issue 2
pp: 131-213

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs. 21(2):202-205, February 2010.

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs. 21(2):210-213, February 2010.